Alto Neuroscience ANRO Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's accrued expenses and other liabilities?
- Alto Neuroscience (ANRO) reported accrued expenses and other liabilities of -$1.75M in Q1 2026.
- How has Alto Neuroscience's accrued expenses and other liabilities changed year-over-year?
- Alto Neuroscience's accrued expenses and other liabilities increased by 35.1% year-over-year, from -$2.7M to -$1.75M.